Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipel
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
11:39am, Thursday, 14'th May 2026
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
08:00am, Thursday, 14'th May 2026
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with i
What's Going On With CNS Pharmaceuticals Stock On Wednesday?
09:51am, Wednesday, 06'th May 2026
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot
09:24am, Monday, 04'th May 2026
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the announcement of an oversubscribed private placement financing expected to generate approximately $2
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
07:00am, Monday, 04'th May 2026
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to e
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
08:35am, Wednesday, 11'th Mar 2026
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic trans
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
08:25am, Monday, 02'nd Mar 2026
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and co
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
08:25am, Tuesday, 17'th Feb 2026
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCES
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened
05:18am, Thursday, 12'th Feb 2026
Shares of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP - Get Free Report) fell 11.2% during mid-day trading on Wednesday. The company traded as low as $3.63 and last traded at $3.63. 32,885 shares were tra
CNS Pharmaceuticals Issues Letter to Shareholders
09:00am, Tuesday, 27'th Jan 2026
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-T
CNS Pharmaceuticals Announces CEO Transition
07:00am, Wednesday, 17'th Dec 2025
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"),
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
01:17pm, Monday, 17'th Nov 2025
CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company Participants John Climaco - CEO, President & Director Christopher Downs - Chief Financial Officer Pre
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
08:35am, Monday, 17'th Nov 2025
Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo
